Dombkowski, who has also worked for hedge fund Tiger Management and institutional asset management firm Dresdner RCM, has more than 15 years of experience as an investor, operating executive and entrepreneur.
Her most recent role was as chief business officer and vice president of operations at consumer genomics company 23andMe.
Bay City founder Fred Craves said, “Drug discovery and development has been transformed by the acceleration of scientific advancements that provide a better understanding of disease biology, generating more effective medicines.
“The relationship among academia, venture-backed startups, and leading multinational pharmaceutical companies has also become more integrated through creative alignment of interests and improved processes.
“Ashley has the expertise and an entrepreneur’s understanding of what it takes to identify investable themes and transform scientific innovation into successful companies.
“Her excellent investment track record adds breadth and depth to our team, positioning us to take full advantage of the most compelling opportunities in this competitive environment.”
Earlier this year Bay City hired experienced biotech operator David Beier as a managing director.
Beier had spent almost a decade as a senior office in businesses Genentech and Amgen, most recently with the latter as senior vice president for global government affairs.
Copyright © 2013 AltAssets